Deal Snapshot: BioNTech and Autolus partner up in a CAR-T deal that will give Autolus more capital ahead of the potential launch of obecabtagene autoleucel.
Who: BioNTech/Autolus
What: The two companies will collaborate on manufacturing, development and commercialization to advance both companies’ autologous CAR-T programs.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers
Private Company Edition: Catalio raised more than $400m for its fourth health care-focused VC fund, while AN Venture Partners raised $200m for Japan and beyond. In VC financings, among a dearth of mega rounds, Neuron23’s $96.5m series D is the largest round in recent weeks.
With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.
